Relevant bibliographies by topics / Pharmaceutical cocrystal systems

Academic literature on the topic 'Pharmaceutical cocrystal systems'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical cocrystal systems.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical cocrystal systems"

1

Mnguni, Malitsatsi J., Joseph P. Michael, and Andreas Lemmerer. "Binary polymorphic cocrystals: an update on the available literature in the Cambridge Structural Database, including a new polymorph of the pharmaceutical 1:1 cocrystal theophylline–3,4-dihydroxybenzoic acid." Acta Crystallographica Section C Structural Chemistry 74, no. 6 (May 23, 2018): 715–20. http://dx.doi.org/10.1107/s2053229618006861.

Full text
Abstract:
An analysis and classification of the 2925 neutral binary organic cocrystals in the Cambridge Structural Database is reported, focusing specifically on those both showing polymorphism and containing an active pharmaceutical ingredient (API). The search was confined to molecules having only C, H, N, O, S and halogens atoms. It was found that 400 out of 2925 cocrystals can be classified as pharmaceutical cocrystals, containing at least one API, and that of those, 56 can be classified as being polymorphic cocrystals. In general, the total number of polymorphic cocrystal systems of any type stands at 125. In addition, a new polymorph of the pharmaceutical cocrystal theophylline–3,4-dihydroxybenzoic acid (1/1), C7H8N4O2·C7H6O4, is reported.
APA, Harvard, Vancouver, ISO, and other styles
2

Leng, Fucheng, Koen Robeyns, and Tom Leyssens. "Urea as a Cocrystal Former—Study of 3 Urea Based Pharmaceutical Cocrystals." Pharmaceutics 13, no. 5 (May 7, 2021): 671. http://dx.doi.org/10.3390/pharmaceutics13050671.

Full text
Abstract:
Cocrystallization is commonly used for its ability to improve the physical properties of APIs, such as solubility, bioavailability, compressibility, etc. The pharmaceutical industry is particularly interested in those cocrystals comprising a GRAS former in connection with the target API. In this work, we focus on the potential of urea as a cocrystal former, identifying three novel pharmaceutical cocrystal systems with catechin, 3-hydroxyl-2-naphthoic and ellagic acid. Interestingly, the stability of catechin under high humidity or high temperature environment is improved upon cocrystallization with urea. Moreover, the solubility of ellagic acid is improved about 17 times. This work displays the latent possibility of urea in improving the physical property of drug molecules using a cocrystallization approach.
APA, Harvard, Vancouver, ISO, and other styles
3

Brittain, Harry G. "Cocrystal Systems of Pharmaceutical Interest: 2010." Crystal Growth & Design 12, no. 2 (January 5, 2012): 1046–54. http://dx.doi.org/10.1021/cg201510n.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Brittain, Harry G. "Cocrystal Systems of Pharmaceutical Interest: 2011." Crystal Growth & Design 12, no. 11 (October 8, 2012): 5823–32. http://dx.doi.org/10.1021/cg301114f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rajput, Lalit, Manas Banik, Jayasubba Reddy Yarava, Sumy Joseph, Manoj Kumar Pandey, Yusuke Nishiyama, and Gautam R. Desiraju. "Exploring the salt–cocrystal continuum with solid-state NMR using natural-abundance samples: implications for crystal engineering." IUCrJ 4, no. 4 (June 5, 2017): 466–75. http://dx.doi.org/10.1107/s205225251700687x.

Full text
Abstract:
There has been significant recent interest in differentiating multicomponent solid forms, such as salts and cocrystals, and, where appropriate, in determining the position of the proton in theX—H...A—YX−...H—A+—Ycontinuum in these systems, owing to the direct relationship of this property to the clinical, regulatory and legal requirements for an active pharmaceutical ingredient (API). In the present study, solid forms of simple cocrystals/salts were investigated by high-field (700 MHz) solid-state NMR (ssNMR) using samples with naturally abundant15N nuclei. Four model compounds in a series of prototypical salt/cocrystal/continuum systems exhibiting {PyN...H—O—}/{PyN+—H...O−} hydrogen bonds (Py is pyridine) were selected and prepared. The crystal structures were determined at both low and room temperature using X-ray diffraction. The H-atom positions were determined by measuring the15N—1H distances through15N-1H dipolar interactions using two-dimensional inversely proton-detected cross polarization with variable contact-time (invCP-VC)1H→15N→1H experiments at ultrafast (νR≥ 60–70 kHz) magic angle spinning (MAS) frequency. It is observed that this method is sensitive enough to determine the proton position even in a continuum where an ambiguity of terminology for the solid form often arises. This work, while carried out on simple systems, has implications in the pharmaceutical industry where the salt/cocrystal/continuum condition of APIs is considered seriously.
APA, Harvard, Vancouver, ISO, and other styles
6

Wong, Si Nga, Susan Wing Sze Chan, Xuexin Peng, Bianfei Xuan, Hok Wai Lee, Henry H. Y. Tong, and Shing Fung Chow. "Effects of the Glass-Forming Ability and Annealing Conditions on Cocrystallization Behaviors via Rapid Solvent Removal: A Case Study of Voriconazole." Pharmaceutics 12, no. 12 (December 14, 2020): 1209. http://dx.doi.org/10.3390/pharmaceutics12121209.

Full text
Abstract:
The kinetic entrapment of molecules in an amorphous phase is a common obstacle to cocrystal screening using rapid solvent removal, especially for drugs with a moderate or high glass-forming ability (GFA). The aim of this study was to elucidate the effects of the coformer’s GFA and annealing conditions on the nature of amorphous phase transformation to the cocrystal counterpart. Attempts were made to cocrystallize voriconazole (VRC) with four structural analogues, namely fumaric acid (FUM), tartaric acid (TAR), malic acid (MAL), and maleic acid (MAE). The overall GFA of VRC binary systems increased with decreasing glass transition temperatures (Tgs) of these diacids, which appeared as a critical parameter for predicting the cocrystallization propensity such that a high-Tg coformer is more desirable. A new 1:1 VRC-TAR cocrystal was successfully produced via a supercooled-mediated re-cocrystallization process, and characterized by PXRD, DSC, and FTIR. The cocrystal purity against the annealing temperature displayed a bell-shaped curve, with a threshold at 40 °C. The isothermal phase purity improved with annealing and adhered to the Kolmogorov–Johnson–Mehl–Avrami kinetics. The superior dissolution behavior of the VRC-TAR cocrystal could minimize VRC precipitation upon gastric emptying. This study offers a simple but useful guide for efficient cocrystal screening based on the Tg of structurally similar coformers, annealing temperature, and time.
APA, Harvard, Vancouver, ISO, and other styles
7

Kaur, Navpreet, Naga Kiran Duggirala, Seema Thakral, and Raj Suryanarayanan. "Role of Lattice Disorder in Water-Mediated Dissociation of Pharmaceutical Cocrystal Systems." Molecular Pharmaceutics 16, no. 7 (May 22, 2019): 3167–77. http://dx.doi.org/10.1021/acs.molpharmaceut.9b00386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bordignon, Simone, Paolo Cerreia Vioglio, Elena Amadio, Federica Rossi, Emanuele Priola, Dario Voinovich, Roberto Gobetto, and Michele R. Chierotti. "Molecular Crystal Forms of Antitubercular Ethionamide with Dicarboxylic Acids: Solid-State Properties and a Combined Structural and Spectroscopic Study." Pharmaceutics 12, no. 9 (August 28, 2020): 818. http://dx.doi.org/10.3390/pharmaceutics12090818.

Full text
Abstract:
We report on the preparation, characterization, and bioavailability properties of three new crystal forms of ethionamide, an antitubercular agent used in the treatment of drug-resistant tuberculosis. The new adducts were obtained by combining the active pharmaceutical ingredient with three dicarboxylic acids, namely glutaric, malonic and tartaric acid, in equimolar ratios. Crystal structures were obtained for all three adducts and were compared with two previously reported multicomponent systems of ethionamide with maleic and fumaric acid. The ethionamide-glutaric acid and the ethionamide-malonic acid adducts were thoroughly characterized by means of solid-state NMR (13C and 15N Cross-Polarization Magic Angle Spinning or CPMAS) to confirm the position of the carboxylic proton, and they were found to be a cocrystal and a salt, respectively; they were compared with two previously reported multicomponent systems of ethionamide with maleic and fumaric acid. Ethionamide-tartaric acid was found to be a rare example of kryptoracemic cocrystal. In vitro bioavailability enhancements up to a factor 3 compared to pure ethionamide were assessed for all obtained adducts.
APA, Harvard, Vancouver, ISO, and other styles
9

Birolo, Rebecca, Federica Bravetti, Simone Bordignon, Ilenia D’Abbrunzo, Paolo P. Mazzeo, Beatrice Perissutti, Alessia Bacchi, Michele R. Chierotti, and Roberto Gobetto. "Overcoming the Drawbacks of Sulpiride by Means of New Crystal Forms." Pharmaceutics 14, no. 9 (August 23, 2022): 1754. http://dx.doi.org/10.3390/pharmaceutics14091754.

Full text
Abstract:
This study aims at developing new multicomponent crystal forms of sulpiride, an antipsychotic drug. The main goal was to improve its solubility since it belongs to class IV of the BCS. Nine new adducts were obtained by combining the active pharmaceutical ingredient with acid coformers: a salt cocrystal and eight molecular salts. In addition, three novel co-drugs, of which two are molecular salts and one is a cocrystal, were also achieved. All samples were characterized in the solid state by complementary techniques (i.e., infrared spectroscopy, powder X-ray diffraction and solid-state NMR). For systems for which it was possible to obtain good-quality single crystals, the structure was solved by single crystal X-ray diffraction (SCXRD). SCXRD combined with solid-state NMR were used to evaluate the ionic or neutral character of the adducts. In vitro dissolution tests of the new crystal forms were performed and all the adducts display remarkable dissolution properties with respect to pure sulpiride.
APA, Harvard, Vancouver, ISO, and other styles
10

Perlovich, German L. "Thermodynamic characteristics of cocrystal formation and melting points for rational design of pharmaceutical two-component systems." CrystEngComm 17, no. 37 (2015): 7019–28. http://dx.doi.org/10.1039/c5ce00992h.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical cocrystal systems"

1

Elbagerma, Mohamed A. "Analytical method development for structural studies of pharmaceutical and related materials in solution and solid state : an investigation of the solid forms and mechanisms of formation of cocrystal systems using vibrational spectroscopic and X-ray diffraction techniques." Thesis, University of Bradford, 2010. http://hdl.handle.net/10454/4467.

Full text
Abstract:
Analysis of the molecular speciation of organic compounds in solution is essential for the understanding of ionic complexation. The Raman spectroscopic technique was chosen for this purpose because it allows the identification of compounds in different states and it can give information about the molecular geometry from the analysis of the vibrational spectra. In this research the ionisation steps of relevant pharmaceutical material have been studied by means of potentiometry coupled with Raman spectroscopy; the protonation and deprotonation behaviour of the molecules were studied in different pH regions. The abundance of the different species in the Raman spectra of aqueous salicylic acid, paracetamol, citric acid and salicylaldoxime have been identified, characterised and confirmed by numerical treatment of the observed spectral data using a multiwavelength curve-fitting program. The non-destructive nature of the Raman spectroscopic technique and the success of the application of the multiwavelength curve-fitting program demonstrated in this work have offered a new dimension for the rapid identification and characterisation of pharmaceuticals in solution and have indicated the direction of further research. The work also covers the formation of novel cocrystal systems with pharmaceutically relevant materials. The existence of new cocrystals of salicylic acid-nicotinic acid, DLphenylalanine , 6-hydroxynicotinic acid, and 3,4-dihydroxybenzoic acid with oxalic acid have been identified from stoichiometric mixtures using combined techniques of Raman spectroscopy (dispersive and transmission TRS), X-ray powder diffraction and thermal analysis. Raman spectroscopy has been used to demonstrate a number of important aspects regarding the nature of the molecular interactions in the cocrystal. Cocrystals of salicylic acid - benzamide, citric acid-paracetamol and citric acid -benzamide have been identified with similar analytical approaches and structurally characterised in detail with single crystal X-ray diffraction. From these studies the high selectivity and direct micro sampling of Raman spectroscopy make it possible to identify spectral contributions from each chemical constituent by a peak wavenumber comparison of single-component spectra (API and guest individually) and the two- component sample material (API/guest), thus allowing a direct assessment of cocrystal formation to be made. Correlation of information from Raman spectra have been made to the X-ray diffraction and thermal analysis results. Transmission Raman Spectroscopy has been applied to the study cocrystals for the first time. Identification of new phases of analysis of the low wavenumber Raman bands is demonstrated to be a key advantage of the TRS technique.
APA, Harvard, Vancouver, ISO, and other styles
2

Qiao, Ning. "Investigation of carbamazepine-nicotinamide cocrystal solubility and dissolution by a UV imaging system." Thesis, De Montfort University, 2014. http://hdl.handle.net/2086/10201.

Full text
Abstract:
In this study, the ability of pharmaceutical cocrystals on improving solubility and dissolution behaviour of poorly water soluble drug has been studied by a novel technique SDI300 UV imaging surface dissolution system. Pharmaceutical cocrystals of poorly water soluble drug carbamazepine (CBZ) were synthesized, which are 1: 1 carbamazepine - nicotinamide (CBZ-NIC) cocrystal, and 2:1 carbamazepine - succinic acid (CBZ-SUC) cocrystal. Firstly, dissolution and solution mediated phase transformation behaviour (SMPT) of CBZ-NIC cocrystal was studied by in situ techniques of UV imaging and Raman spectroscopy. This study has shown that in situ UV imaging and Raman spectroscopy with a complementary technique of SEM can provide an in depth understanding of cocrystal dissolution processes. It has been found that CBZ-NIC cocrystal including other polymorphs of CBZ III and I and mixture are converting to CBZ DH during dissolution. The influence of surfactants, SLS and Tween 80, on the solubility and dissolution behavior of the CBZ-NIC cocrystal has been studied. Results show that the SMPT of CBZ III and CBZ-NIC cocrystal can be altered by inclusion of a surfactant in dissolution medium. However, CBZ III and CBZ-NIC cocrystal have shown different transformation behavior with different surfactants. The solubility and dissolution behaviour of CBZ-NIC cocrystal, CBZ-SUC cocrystal in four biomedia (simulated gastric fluid, pH1.2 HCl buffer, simulated intestinal fluid, and pH 6.8 PBS buffer) were studied. Results have shown that equilibrium solubility of CBZ samples varied in different media. The two cocrystals dissolution rates show different trends as that of parent drug CBZ III. This can be explained by that the formation of cocrystal change the dissolution ability of CBZ III.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmaceutical cocrystal systems"

1

Brittain, Harry G. "Cocrystal Systems of Pharmaceutical Interest: 2009." In Profiles of Drug Substances, Excipients and Related Methodology, 361–81. Elsevier, 2011. http://dx.doi.org/10.1016/b978-0-12-387667-6.00010-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brittain, Harry G. "Cocrystal Systems of Pharmaceutical Interest: 2012–2014." In Profiles of Drug Substances, Excipients and Related Methodology, 415–43. Elsevier, 2019. http://dx.doi.org/10.1016/bs.podrm.2018.11.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Brittain, Harry G. "Cocrystal Systems of Pharmaceutical Interest: 2007–2008." In Profiles of Drug Substances, Excipients and Related Methodology, 373–90. Elsevier, 2010. http://dx.doi.org/10.1016/s1871-5125(10)35009-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical cocrystal systems' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography